Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

First Edition: July 27, 2012

Today's headlines include reports about a new effort launched by the Obama administration and insurers to fight health care fraud.

27 Jul 2012

Burgess to offer legislation to fund high-risk pools, reinsurance programs

Rep. Michael Burgess, R-Texas, plans to offer the bill before the August recess. Meanwhile, after fighting back a tea-party primary challenge, Sen. Orrin Hatch, R-Utah, hopes to emerge as a dealmaker on tax and budget issues.

25 Jul 2012

First Edition: July 24, 2012

Today's headlines include news from the campaign season as well as reports from the international AIDS conference currently taking place in Washington, D.C.

24 Jul 2012

Research roundup: Medication adherence, performance at community health centers

For people diagnosed with depression, it's important that they adhere to their medication regimen so that they avoid recurrent episodes. But because of Medicare's Part D coverage gap, financially burdened seniors might not take their prescriptions as recommended. This study looked at Medicare beneficiaries diagnosed with depression in 2007.

14 Jul 2012

U.K. High Court rules in favor of Teva in COPAXONE patent litigation

Teva Pharmaceutical Industries Ltd. announced that the United Kingdom High Court of Justice issued a decision in favor of Teva in a patent litigation proceeding against Generics (UK) Limited, a subsidiary of Mylan Laboratories Inc., on July 11, 2012.

12 Jul 2012

July issue of Health Affairs examining PEPFAR impact to be discussed at briefing on Tuesday

The July 2012 issue of Health Affairs, published Monday, examines the impact of PEPFAR, focusing on "the origins of the program; the lessons learned from implementation; the successes achieved in terms of human health and well-being; and the opportunities that now exist to lay the groundwork for an 'AIDS-free generation,'" the Health Affairs Blog reports, noting, "The new Health Affairs issue will be discussed Tuesday morning at a Washington, D.C., briefing."

11 Jul 2012

Clinical results for Teva's biologic oncology candidates presented at MASCC/ISOO 2012

Teva Pharmaceutical Industries Ltd. announced today the presentation of clinical results for its biologic oncology candidates, lipegfilgrastim and balugrastim, at the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) 2012 International Symposium on Supportive Care in Cancer being held in New York June 28-30.

2 Jul 2012

U.S. District Court rules in favor of Teva in COPAXONE patent infringement case

Teva Pharmaceutical Industries Ltd. announced today the U.S. District Court for the Southern District of New York has found in favor of Teva in the Company's patent infringement lawsuit against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Laboratories Inc./Natco Pharmaceuticals regarding Teva's relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE.

23 Jun 2012

No legal recourse because generic drug caused injury

Carrie Scott went in to the hospital for abnormal bleeding. Days later she returned home without her hand and forearm. The generic form of Phenergan was given improperly, apparently from an inadequate warning label. Scott has no legal recourse because a generic drug caused her injury, rather than its brand-name equivalent.

22 Jun 2012

Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Teva Pharmaceutical Industries Ltd. announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.

22 Jun 2012

Mylan's new online resource seeks to dispel common misconceptions about generic drugs

Mylan Pharmaceuticals ULC, the Canadian subsidiary of Mylan Inc., announced today the introduction of a new online resource, ChoosingGenerics.ca, to help Canadians learn more about the value, reliability and quality of generic pharmaceuticals. The website is a public awareness tool that seeks to dispel common misconceptions and help Canadians learn more about the benefits of generic drugs.

18 Jun 2012

Senate Appropriations boosts HHS funding on party-line vote as GOP attacks health reform provisions

Partisan wrangling over the health law, as well as funding of HHS, is continuing on Capitol Hill.

16 Jun 2012

Positive top-line results from Teva’s GALA Phase III trial on RRMS

Teva Pharmaceutical Industries Ltd. today announced positive top-line results from the GALA (Glatiramer Acetate Low-Frequency Administration) Phase III clinical trial assessing the efficacy, safety and tolerability of 40 mg/1 ml glatiramer acetate injection (GA) administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis (RRMS) patients.

15 Jun 2012

Global generic pharmaceuticals market to reach $231.00 billion in 2017 at 9.29% CAGR

The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs and the judicious cost containment efforts of governments and healthcare service providers worldwide.

2 Jun 2012

Sihuan's Roxatidine passes Chinese SFDA on-site inspection

Sihuan Pharmaceutical Holdings Group Ltd., a leading pharmaceutical company with the largest cardio-cerebral vascular drug franchise in China's prescription market, announced that Roxatidine Acetate Hydrochloride for Injection, Sihuan Pharmaceutical's first-to-market generic drug, recently passed on-site inspection for drug registration conducted by the Chinese State Food and Drug Administration.

25 May 2012

Is access problem preventing generic drug makers' progress?

Some drugmakers assert they are unable to create cheaper generic versions of drugs because their rivals are exploiting a legal loophole. It all comes down to process: To get a generic drug approved for sale, a company has to test a sample of the brand-name version and show regulators that the generic version is essentially identical and as effective.

24 May 2012